- Clinical Expertise
- Genito-Urinary Cancers
- Board Certifications
- Internal Medicine
- Medical Oncology
- Appointments
- Associate Professor of Medicine, Columbia University Medical Center
- Education
- B.A., 1981, Columbia College , New York, NY
- M.D., 1985, Case Western Reserve University School of Medicine, Cleveland, OH
- Internship & Residency
- Internal Medicine, 1988, Jacobi Hospital, Albert Einstein College of Medicine, Bronx, NY
- Fellowship
- Medical Oncology, 1991, Memorial Sloan-Kettering Cancer Center, New York, NY
Daniel Petrylak, M.D.
NEW PATIENTS TEL (212) 305-5098
ADMINISTRATIVE OFFICE TEL (212) 305-1731
FAX (212) 305-6762
- OUTPATIENT OFFICE LOCATION
- Irving Pavilion 9 919
- 161 Fort Washington Ave at W 165th St..
- PHYSICIAN SUMMARY
-
Professor of Medicine, Program Director of the Genitourinary Oncology Section in the Division of Hematology/Oncology and Co-Leader, Prostate Cancer in the Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center
Dr. Petrylak received his medical degree from Case Western Reserve University School of Medicine, and completed his Internal Medicine residency at Albert Einstein College of Medicine/Jacobi Medical Center. He did his Medical Oncology fellowship at Memorial Sloan Kettering Cancer Center. He was appointed to a faculty position at Columbia University in 1991. Dr. Petrylak conducts clinical research in genitourinary malignancies and is a national leader in clinical trials for advanced prostate cancer. He also conducts research in bladder cancer is the head of the Advanced Bladder Subcommittee in the Southwest Oncology Group Genitourinary Committee. Dr. Petrylak has served as principal investigator or co-principal investigator on 7 Southwest Oncology Group Protocols. Most notably, he served as the PI for a randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone in men with hormone refractory prostate cancer. This trial was one of two studies that demonstrated a survival benefit for docetaxel-based therapy in men with advanced prostate cancer. This trial supported the approval of docetaxel for hormone refractory prostate cancer by the FDA. He also helped to design and served as PI for the SPARC trial, an international registration trial evaluating the activity of satraplatin as a second line therapy for hormone refractory prostate cancer. Dr. Petrylak is recognized internationally as an expert in the treatment of GU malignancies. He has served on the program committee for the annual meetings of the American Urological Association (2003-9) as well as for the American Society of Clinical Oncology (1995-7, 2001-3). He has been on the Education Committee of ASCO. He also has served as a committee member for the Devices and Immunolgicals section of the Food and Drug Administration. He has published extensively, in the New England Journal of Medicine, Journal of Clinical Oncology, Journal of the National Cancer Institute, as well as Cancer Research and Clinical Cancer Research.